Mizraji M
National Institute of Rheumatology, Montevideo, Uruguay.
Eur J Rheumatol Inflamm. 1990;10(1):35-43.
Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID). Published and unpublished data on etodolac in pain management are reviewed to assess the analgesic effectiveness of this drug. Data are presented from four representative studies that showed the analgesic activity of etodolac in postsurgical pain models. These results suggest that the drug would have analgesic utility in other painful conditions such as gout and musculoskeletal disorders. The efficacy of etodolac in such conditions is confirmed by the results from eight controlled clinical studies in patients with gouty arthritis, tendinitis and bursitis, and acute sports injuries. Etodolac 200 or 300 mg twice a day (b.i.d.) or 200 mg three times a day (t.i.d.) was compared with naproxen 500 mg b.i.d. and diclofenac 50 mg b.i.d. or 50 mg t.i.d. All three NSAIDs provided analgesia, and etodolac was comparable in efficacy to the comparators. The data presented in this review suggest a future role for etodolac as an analgesic as well as an anti-inflammatory agent.
依托度酸是一种新型非甾体抗炎药（NSAID）。本文回顾了已发表和未发表的关于依托度酸在疼痛管理方面的数据，以评估该药物的镇痛效果。数据来自四项具有代表性的研究，这些研究显示了依托度酸在术后疼痛模型中的镇痛活性。这些结果表明，该药物在痛风和肌肉骨骼疾病等其他疼痛病症中可能具有镇痛作用。八项针对痛风性关节炎、肌腱炎和滑囊炎以及急性运动损伤患者的对照临床研究结果证实了依托度酸在这些病症中的疗效。将依托度酸200或300毫克每日两次（b.i.d.）或200毫克每日三次（t.i.d.）与萘普生500毫克每日两次以及双氯芬酸50毫克每日两次或50毫克每日三次进行比较。所有三种NSAIDs均提供了镇痛作用，且依托度酸的疗效与对照药物相当。本综述中呈现的数据表明，依托度酸未来可作为一种镇痛药以及抗炎药发挥作用。
